Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUSNHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to Share XScotland backs NHS use of Alexion’s Ultomiris for rare disease aHUShttps://pharmaphorum.com/news/scotland-backs-nhs-use-of-alexions-ultomiris-for-rare-disease-ahus/
NICE talking to you: Trends in early HTA engagementWith exclusive data from Freedom of Information (FOI) requests sent to the National Institute for Health and are Share XNICE talking to you: Trends in early HTA engagementhttps://pharmaphorum.com/views-analysis-market-access/nice-talking-to-you/
Improving access and reimbursement for specialty therapiesAs specialty therapies move toward long-term maintenance use and as treatment times grow longer, government and commercial payers Share XImproving access and reimbursement for specialty therapieshttps://deep-dive.pharmaphorum.com/magazine/market-access-2020/improving-access-and-reimbursement-for-specialty-therapies/
NICE names Gillian Leng as CEO, replacing Andrew DillonNICE has appointed Prof Gillian Leng as its new chief executive, completing its top leadership search after new Share XNICE names Gillian Leng as CEO, replacing Andrew Dillonhttps://pharmaphorum.com/news/nice-names-gillian-leng-as-ceo-replacing-andrew-dillon/
MPs back Nebhrajani as NICE’s new chair after vetting meetingSharmila Nebhrajani has been confirmed as the new chair of the National Institute for Health and Care Excellence Share XMPs back Nebhrajani as NICE’s new chair after vetting meetinghttps://pharmaphorum.com/news/mps-back-nebhrajani-as-nices-new-chair-after-vetting-meeting/
NICE chair nominee Nebhrajani to face MP scrutiny next weekThe UK government’s preferred candidate to chair NICE – Sharmila Nebhrajani OBE – is due to be quizzed Share XNICE chair nominee Nebhrajani to face MP scrutiny next weekhttps://pharmaphorum.com/news/nice-chair-nominee-nebhrajani-to-face-mp-scrutiny-next-week/
ICER methods could be illegal in US, claims US think tankThe method used by the US Institute for Clinical and Economic Review (ICER) to gauge whether drugs are Share XICER methods could be illegal in US, claims US think tankhttps://pharmaphorum.com/news/icer-methods-could-be-illegal-in-us-claims-us-think-tank/
Scotland backs AZ’s Lynparza for first-line ovarian cancer maintenanceThe Scottish Medicines Consortium (SMC) has backed routine funding of AstraZeneca and MSD’s Lynparza as a maintenance treatment Share XScotland backs AZ’s Lynparza for first-line ovarian cancer maintenancehttps://pharmaphorum.com/news/scotland-backs-azs-lynparza-for-first-line-ovarian-cancer-maintenance/
Division on European HTAThere have been aspirations for closer collaboration between European Union (EU) Member States (MS) on Health Technology Assessment Share XDivision on European HTAhttps://pharmaphorum.com/views-and-analysis/hta-european-health-technology-assessment-division-progress/
